Riccardo Cortese
Nessuna posizione attualmente
Profilo
Riccardo Cortese was the Chairman & Chief Executive Officer of Nouscom AG, a company he founded in 2007.
He was also the founder of ReiThera Srl, established in 2005, and Okairos AG, founded in 2007, where he served as the Chief Executive Officer & Managing Director from 2010 to 2014.
In addition to his founding positions, Dr. Cortese has held former job titles such as Chief Executive Officer at Advent SRL, Scientific Director at Merck & Co., Inc., Independent Director at AGC Biologics SpA, Professor at Università degli Studi di Napoli Federico II, and Member at JV Bio SRL.
Dr. Cortese obtained a doctorate degree from the University of California, Berkeley, and an undergraduate degree from Università degli Studi di Napoli Federico II.
Precedenti posizioni note di Riccardo Cortese
| Società | Posizione | Fine |
|---|---|---|
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Chief Executive Officer | 01/04/2017 |
| Advent SRL | Chief Executive Officer | 01/04/2017 |
| JV Bio SRL | Corporate Officer/Principal | 01/04/2017 |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Chief Executive Officer | - |
| Università degli Studi di Napoli Federico II | Corporate Officer/Principal | - |
Formazione di Riccardo Cortese
| University of California, Berkeley | Doctorate Degree |
| Università degli Studi di Napoli Federico II | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Aziende private | 6 |
|---|---|
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Okairos AG
Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
Reithera Srl
 Reithera Srl Real Estate Investment TrustsFinance Reithera Srl is a biotech company based in Rome, Italy. The Italian company specializes in viral vector production and is a leading contract development and manufacturing organization. The company has a new 1,500 sq.m. facility that has been granted operational authorization from AIFA, the Italian Medicines Agency, which will allow them to consolidate their competitive position. Reithera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. The company aims to unlock the potential of vector gene-delivery platforms by exploiting adenovirus, MVA, AAV, helper-dependent vectors, and rhabdovirus. The CEO of the company is Antonella Folgori. | Finance |
| Advent SRL | |
| JV Bio SRL |
- Borsa valori
- Insiders
- Riccardo Cortese
